Related Experiment Video

Updated: May 9, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review

Ping Ma1, Russell J Mumper

  • 1Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Nano Today
|July 27, 2013
PubMed

Insights

Anthracycline chemotherapy faces limitations due to multidrug resistance (MDR). Novel nano-delivery systems show promise in overcoming MDR, with various types advancing in research and clinical trials.

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • Anthracyclines are effective chemotherapy drugs but their use is limited by multidrug resistance (MDR).
  • MDR significantly hinders the clinical application of anthracyclines in cancer treatment.
  • Nano-delivery systems offer a promising strategy to overcome MDR in cancer therapy.

Purpose of the Study:

  • To review and discuss various anthracycline nano-delivery systems developed to overcome MDR.
  • To explore the proposed mechanisms by which these nano-delivery systems circumvent MDR.
  • To provide a comprehensive overview of advancements in anthracycline nanotechnology for cancer treatment.

Main Methods:

  • Comprehensive literature review of anthracycline nano-delivery systems.
  • Analysis of diverse nano-delivery platforms including liposomes, micelles, nanoparticles, and conjugates.
  • Discussion of proposed mechanisms of action for overcoming MDR.

Main Results:

  • Over ten types of anthracycline nano-delivery systems have been developed to combat MDR.
  • These systems include liposomes, polymeric micelles, conjugates, various nanoparticles (solid-lipid, magnetic, gold, silica, cyclodextrin), and carbon nanotubes.
  • Many systems demonstrate efficacy in overcoming MDR both in vitro and in vivo, with some progressing to clinical trials.

Conclusions:

  • Nano-delivery systems represent a significant advancement in overcoming anthracycline resistance in cancer.
  • Diverse nanotechnology platforms offer potential solutions to enhance chemotherapy efficacy.
  • Continued research and development of these systems are crucial for improving cancer treatment outcomes.
Keywords:
anthracyclinesmulti-drug resistancenanoparticles

More Related Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Drug Delivery: Overview01:16

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...